01
What makes us different
Most RNA solutions address a single step of the workflow. Quantoom brings design, production and delivery together in one platform, so every step is proven in its own right and consistent with the next.
About us
Discover Quantoom Biosciences: pioneering RNA manufacturing solutions and innovative mRNA technologies for global healthcare advancement
What we stand for
Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-CNP drug product: Ncode for sequence design and optimization, Ntensify® for RNA production and Ncapsulate® for RNA-CNP formulation. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization.
Our expertise & offering
In this context, Quantoom is offering the first end-to-end unified RNA platform:
Quantoom has combined mRNA design, production, and delivery into one standardized workflow, enabling customers to develop mRNA medicines faster, at lower cost, with greater flexibility and freedom to operate.
We think that Quantoom's unique right to win is based on:
02
Three very different target markets, one platform
Complementary business models with infectious diseases as the recurring revenue backbone, animal health as the near-term growth engine and personalized oncology as the long-term value driver.
Personalized oncologyInfectious diseasesAnimal health
03
Flexible adoption model
Start with a joint R&D project, then bring the technology into your own facility once it has proven itself. We support you at every stage, with the reagents, training and licensing each one calls for.
Our partners
Our global collaborations
Since its commercial launch in 2023, Quantoom Biosciences has installed 25 Ntensify® systems worldwide and has five ongoing R&D collaborations.
Diversity & values
At Quantoom Biosciences, we stand for inclusivity, diversity, and respect for individual differences. We strive to practice equality across the board, from our hiring methods to how we pay employees. Our team represents many diverse backgrounds and perspectives.
Accountability
We own and assume accountability for results, we establish high-performance standards
Continuous improvement
We challenge the status quo, embrace innovation, add value, and deliver operational excellence
Teach/lead
We value and solicit new ideas, develop and refine competencies by sharing knowledge and experience
Integrity
We maintain high ethical standards; respect, include and recognize differences
Team
Everyone acts as a team builder, we remove the barriers that block the team's success
Board
Click on each picture to see the bio of each member
Commercial team
Our Commercial team operates globally, ensuring seamless support in every region
Maria Davila-Saignol
Global Director Sales & Business Dev.
Didier Argentin
Director Sales Europe
Emilie Viey
Director Sales North America
James Timmins
Senior Business Developer, North America
Wen Hong Toh
Senior Business Developer, APAC
Hilde Vrancken
Senior B.D - Animal Health Expert
Scientific & Technical Committee
N-Force Product Team
N-Force Services Team
Marketing and Sales Operations
Our Marketing and Sales operations team connects Quantoom's RNA innovations with the scientists, partners and communities we serve worldwide
Thomas Guyon
Marketing Manager • Product Marketing
Nicolas Dantinne
MarCom Manager
Jessica Van Berlamont
Marketing and Sales Officer
Finance and HR
Our Finance and HR teams support Quantoom's growth — from talent and culture to the financial backbone of our operations
Jean-François Art
Talent Acquisition Specialist / Human Resources
Sandra Vimeux
Senior Accountant
Chaimae Laafare
Finance & Business Controller
Operations and QA Team
Our Operations and QA Team keeps Quantoom running smoothly — from the C.E.O office to the lab and supply chain
Nathalie Dumoulin
QA Manager
Marc De Fruytier
Site Manager
Wendy Glasset
Executive Assistant • CEO Office
Helène Larsimont
Project Manager
Thierry Ruymaekers
Import - Export Expert
Amaury Patris
Logistic Technician
Hanaa El Qortobi
QA support
Sophie Lejour
Senior lab technician and procurement
Sophie Massart
Senior lab technician and procurement
AC
Angélique Coppens
Quality assurance & Scientific-regulatory-technical writer
Our history
Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Built around our N-Force toolbox — Ncode for sequence design, Ntensify® for scalable RNA production, and Ncapsulate® for RNA-CNP formulation — our platform turns any antigen into a high-quality (sa)mRNA-CNP drug product. Beyond technology, Quantoom Biosciences supports partners with extensive enabling services, from strategic R&D collaborations to sequence design and optimization.
Quantoom Biosciences Appoints Soter Bio as Exclusive North America RNA CDMO for RUO and GMP Manufacturing
Quantoom Biosciences, a leader in integrated RNA-CNP manufacturing technologies, today announced Soter Bio as its exclusive RNA Contract Development and Manufacturing Organization (CDMO) for both Research Use Only (RUO) and GMP manufacturing across North America, including the United States, Canada, and Mexico. This designation establishes a dedicated U.S.-based platform for end-to-end RNA manufacturing, from DNA through RNA drug product and fill/finish, supporting programs from early research through clinical and commercial supply using Quantoom's closed, automated GMP manufacturing systems.
Read the press release →February
2026
December
2025
University of Western Australia selects Ntensify® mini for advanced RNA research
The University of Western Australia's RNA Innovation Foundry selects Quantoom Biosciences' Ntensify® mini platform to support cutting-edge RNA research and technology development. This adoption highlights Quantoom's growing footprint in academic research and innovation ecosystems, and its role in enabling the next generation of RNA-based therapies.
Read the press release →Restructuring and creation of Phoenix Biosciences as a standalone company
Quantoom Biosciences enters a new phase under the legal entity Phoenix Biosciences SA, through which all activities and technologies now continue. Spun out of Univercells in October 2025 during the holding company's bankruptcy, strategic suppliers, customers and revenue were retained under a cleaner, leaner structure. This restructuring provides a clear and solid foundation for the future, strengthening our position as a full-stack RNA solutions provider, with new funding:
- Oct 2025 – Seed funding 4.3M€
- Dec 2025 – Series-A 2M€ + 3M€ Loan
October
2025
September
2025
Research collaboration with Leading Global Cancer Center
Quantoom Biosciences signs a research license and supply agreement with Memorial Sloan Kettering Cancer Center to support the development of personalized mRNA-based cancer therapeutics. This collaboration confirms Quantoom's expansion into high-value clinical research and oncology applications, reinforcing the versatility of its mRNA formulation and manufacturing technologies.
Read the press release →Launch of the Ntensify® micro
Quantoom Biosciences launches the Ntensify® micro, expanding the R&D segment of its Ntensify® product line. The Ntensify® micro is the smallest and most compact system designed for the Ntensify® process. This benchtop unit enables the production and purification of 500 µg to 100 mg of high-quality mRNA in just 4 to 6 hours.
March
2025
November
2024
Belgium and Brazil unite to advance RNA-based therapies
Quantoom Biosciences signs a Memorandum of Understanding with Bio-Manguinhos/Fiocruz, strengthening international cooperation to accelerate the development and local production of RNA-based therapeutics. This milestone reflects Quantoom's growing role as a global technology enabler, supporting sovereign manufacturing strategies beyond vaccines.
Read the press release →Strategic collaboration with Serum Institute of India
Quantoom Biosciences enters into a strategic collaboration with the world's largest vaccine manufacturer to expand the accessibility of RNA-based personalized oncology and immunotherapies. This partnership marks a major step beyond vaccines, demonstrating Quantoom's ability to support point-of-care, small-scale mRNA manufacturing for advanced therapeutic applications worldwide.
April
2024
March
2024
Launch of the Ntensify® mano
Quantoom Biosciences announces the extension of the Ntensify® product line with the launch of Ntensify® mano, an mRNA kit containing mixes of reagents for mRNA production and purification for research use.
Read the press release →Installation of the 1st Ntensify® midi
Quantoom Biosciences announces the installation of its first Ntensify® midi system for mRNA vaccine production in the GMP facility of Afrigen Biologics in Cape Town, South Africa.
Read the press release →May
2023
June
2022
Agreement for the first African-owned Covid-19 vaccine
The collaboration with Afrigen Biologics (hosting the World Health Organization's Global mRNA Vaccine Technology Transfer Hub) will focus on the development of a novel mRNA vaccine that will drastically accelerate access to vaccination by using Quantoom's mRNA production technology.
Collaboration with eTheRNA
Quantoom entered into a strategic collaboration to build an advanced, small footprint technology platform for the affordable production of RNA-based therapies. This platform was designed to be used either within existing facilities or rapidly deployed to areas of urgent need.
July
2021
June
2021
Official launch of Quantoom Biosciences
The COVID-19 pandemic underlined the desperate need for technological innovation in manufacturing to provide a simple, scalable way to make RNA. By lowering the barriers to RNA production, we allow our partners that have previously not considered exploring RNA-based vaccines and therapeutics, to gain access to RNA production capabilities and enter the market.